Response-adapted therapy (tx) with nivolumab plus brentuximab vedotin (nivo + BV) without autologous hematopoietic cell transplantation (auto-HCT) in children, adolescents, and young adults (CAYA) with low-risk relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL): CheckMate 744
| Published in: | Journal of Clinical Oncology Vol. 41; pp. 7515 - 7516 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Published: |
American Society of Clinical Oncology
2023 Supplement 16
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=164014821&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 164014821 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 0732183X 20D jtl: Journal of Clinical Oncology issn: 0732183X maglogo: N pubinfo: dt: 2023 Supplement 16 vid: 41 pid: 26892 pub: American Society of Clinical Oncology place: Alexandria, Virginia artinfo: ui: 164014821 10.1200/JCO.2023.41.16_suppl.7515 164014821 ppf: 7515 ppct: 1 formats: tig: atl: Response-adapted therapy (tx) with nivolumab plus brentuximab vedotin (nivo + BV) without autologous hematopoietic cell transplantation (auto-HCT) in children, adolescents, and young adults (CAYA) with low-risk relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL): CheckMate 744 aug: au: Harker-Murray, Paul David Cole, Peter D. Hoppe, Bradford S. Hodgson, David C. Beishuizen, Auke Garnier, Nathalie Buffardi, Salvatore Mascarin, Maurizio Lissat, Andrej Akyol, Alev Crowe, Russell Li, Ju Drachtman, Richard A. Kelly, Kara M Leblanc, Thierry Daw, Stephen affil: Children's Wisconsin, Milwaukee, WI sug: pubtype: Academic Journal doctype: Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|